Evolent Q2 revenue falls 31% to $444M, net loss deepens to $51M; raises FY profitability outlook

Evolent Health, Inc.

2025-Q2 EPS reported -$1.07 revenue$927,977,000

Revenue $444.3M, down 31% YoY from $647.1M; net loss $51.1M vs $6.4M loss in prior year.
Adjusted EBITDA $37.5M (8.5% margin) vs $51.9M (8.0% margin); margin improved but absolute EBITDA down 28%.
Performance Suite average lives 6,490, down 6% YoY; average PMPM fee $13.76, down 38% YoY.
CEO says company exceeded EBITDA targets and raised full-year profitability outlook; expects to exceed historical growth rates in 2026.
Year-to-date new revenue agreements total 11; multiple new client additions across Performance Suite and specialty services.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.